---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-001679"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:43:59.530464+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aclaris Q4 net loss $96.6M, revenue $9.2M; cash $203.9M; pipeline catalysts in H1 2025

## Summary
- Net loss $96.6M in Q4 2024 vs $1.5M in Q4 2023; included $86.9M in-process R&D charge from bosakitug license.
- Revenue $9.2M in Q4 2024 vs $17.6M in Q4 2023; full year revenue $18.7M vs $31.2M.
- Cash, equivalents and marketable securities $203.9M at Dec 31, 2024; cash runway expected into 2028.
- Phase 2 data from partner CTTQ in severe asthma and CRSwNP expected H1 2025; Phase 2b for bosakitug in AD enrollment H1 2025.
- Leadership changes: Neal Walker named CEO; Hugh Davis appointed President and COO.

## SEC filing metadata
- accession: 0001558370-25-001679
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837025001679/0001558370-25-001679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837025001679/acrs-20250227x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-001679
- JSON: https://secwatch.observer/filing/0001558370-25-001679.json
- Plain text: https://secwatch.observer/filing/0001558370-25-001679.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.